TTR and melanoma: However, our study indicates that CD44 might represent a promising therapeutic target in combination with targeted therapy in melanoma where anti-CD44 antibodies or other agents blocking CD44-mediated cellular crosstalk could suppress TTR macrophage-driven resistance formation and, hence, could improve therapeutic outcome.